Active Pharmaceutical Ingredients (APIs)

SK Capital Changes Tack on Archroma

Cambrex Expands Charles City API Plant

Lonza Buys Swiss Micronization Technology Specialist Micro-Macinazione

Neuland Laboratories Opens Dedicated Process Engineering Lab

Trinseo to Acquire Italy’s API

Cambrex Invests in Swedish cGMP Facility

Meeting Customers’ Changing Needs

Catalysts for More Efficient Processes

Umicore Facility in Argentinia Passes new European cGMP Audit

Transatlantic Deal Simplifies Pharma Inspections

Ferak Berlin Receives GMP Certification

Lonza Captures Capsugel for $5.5 Billion

The Winning Formula

Cambrex Validates Milan API Pilot Plant

BASF Inaugurates China PVP Plant

Cambrex Announces Investment & Expansion

ISPE Recognizes Leaders in Drug Shortage Prevention

Opportunities in Drug Development and Manufacturing

Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.

A New Pathway

The Possibilities Of Peptides

The Winning Formula

Bridging the Innovation Gap

Piramal Adds Ash Stevens for $53 Million

FDA Warns GSK on Contamination at UK Plant

AMRI Boosts API Business with Euticals Buy

Carbogen Amcis Expanding Swiss Capacity

Recipharm Buys Three Kemwell Businesses

Johnson Matthey and Domainex to Collaborate

Aesica Expands UK Development Capacity

Staying Ahead In Outsourcing

The New Globalism

Ardian in Talks for Sale of Novacap Stake

Dottikon Boosts Swiss API Capacities

US Law Firm Probes Dr. Reddy’s and PTC

DCAT Week ’16